CLINICAL_TRIALS
trial_result
· 2010-01-21
Clinical Trial Update: Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3) [Phase 3]
Summary
Phase 3 trial P04249AM3 evaluating Remicade (infliximab) for retaining response in rheumatoid arthritis was terminated; results were posted January 21, 2010.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Rheumatoid Arthritis | Phase 3 | Status: TERMINATED | Results posted: 2010-01-21